Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Alteogen executed a joint development and license agreement with Swiss pharmaceutical firm Sandoz AG for a novel hyaluronidase distinct from ALT-B4, under which Alteogen will receive milestone payments and running royalties based on net sales upon commercialization.
📊 [Key Disclosure Details & Financial Highlights]
- Contracting Party: Sandoz AG (Switzerland, spun off from Novartis in 2023, 2023 Revenue: $9.6 Billion)
- Scope of Agreement: Joint development and license agreement aimed at developing a hyaluronidase distinct from ALT-B4
- Agreement Date & Term: 2024-07-30 ~ Until expiration of the royalty period
- Key Financial Terms:
- Total Contract Value & Milestones: Detailed milestone amounts for development, regulatory approval, and sales are deferred under confidentiality terms
- First Milestone Payment: Scheduled to be received within January 2025
- Sales Royalties: Running royalties based on a percentage of net sales upon achieving sales targets following first commercial sales in contracted countries
- Refund Obligations: Received contract payments (milestones and royalties) carry no refund obligations
- Disclosure Deferral Details:
- Deferred Items: Specific schedules, development target products, total contract value, and detailed milestone breakdowns
- Reason & Period: Confidentiality agreement / Deferred until 2042-12-28
- Investment Risk Note: Conditional agreement dependent on clinical trial success and regulatory approvals
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Why Verifying Receipt of the First Milestone and Subsequent Development Progress Is Necessary
This filing confirms a global technology export and joint development agreement for a new hyaluronidase technology separate from Alteogen’s main ALT-B4 pipeline.
Checking this follow-up item is necessary because confirming the actual receipt of the first milestone payment within the scheduled timeline (by January 2025) serves as direct evidence verifying the initial execution of this joint development agreement. Furthermore, as specific development targets and total contract values remain non-disclosed under confidentiality terms (deferred through 2042), tracking whether subsequent development milestones and payment receipts are recognized in future filings is essential to verify the ongoing execution of the agreement.
The progress can be confirmed through future disclosures or upcoming periodic reports on DART.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
